- Organizations: Alcon, Inc.
Events
ASRS 2026: industry highlights and product innovations
Annual retina specialists meeting kicks off in Montreal with immersive, interactive experiences and technology showcases.
Pipeline
Alcon and RxSight partner to to develop light-adjustable PCIOLs
Non-exclusive deal will combine Alcon’s presbyopia-correcting IOL optical designs with RxSight’s customizable postop light-adjustable technology.
Products
Alcon introduces expanded parameters across toric contact lens portfolio
Updated ranges apply to its WaterInnovations astigmatism lens portfolio: PRECISION1, PRECISION7, and TOTAL30.
Events
ASCRS 2026 highlights key trends in surgical ecosystem
Annual meeting of cataract and refractive surgeons kicks off in the nation’s capital with focus on developments in surgical devices and IOLs.
Products
Alcon launches Clareon TruPlus monofocal and toric IOL
Latest next-gen IOL features the new Opti-Blance Technology design to increase DOF without sacrificing distance vision quality
Business
Alcon and Lensar terminate proposed merger after FTC pressure
Companies reasoned deal was unlikely to gain regulatory approval as the FTC cited concerns over reduced competition and increased prices within the FLACS space.
Products
Alcon launches TOTAL30 Multifocal for Astigmatism toric contact lens
Designed for astigmatic presbyopes, the latest TOTAL30 is the only monthly MF toric lens featuring proprietary Water Gradient Technology.
Business
STAAR Surgical and Alcon terminate proposed merger
Decision to end the estimated $1.6 billion deal follows a failed vote among STAAR stockholders earlier this week.Business
Alcon proposes higher bid for STAAR Surgical acquisition
Amended merger agreement increases total equity value of deal by $150 million; meanwhile, a major shareholder is urging against the sale.
Products
Alcon unveils updated LenSx OnAxis tech for astigmatism management
New tech enables advanced features such as capsular toric markings, advanced fragmentation patterns, as well as intra- and postoperative IOL verification.
Research
Phase 3b data supports superior tear response with TRYPTYR
Presented at AAO, new findings stem from measuring tear volume produced following administration of the DED drop.
Products
Alcon launches first fully personalized LASIK treatment
The wavelight plus includes ray-tracing technology to create a 3D eye model for a fully-tailored treatment approach for refractive surgery.
Business
Alcon officially purchases LumiThera
Acquisition of the Valeda Light Delivery System includes plans to expand commercial market availability in 2026.Business
Alcon to acquire STAAR Surgical
The $1.5 billion deal includes STAAR’s FDA-approved implantable collamer lenses; expected to close within 6 to 12 months.Products
Alcon's TRYPTYR launches to the US market
Company’s first-in-class, prescription-based pharmaceutical features acoltremon, making it the first topical neuromodulator to rapidly increase tear production for DED.
Business
Leadership watch: ViaLase, J&J, Alcon, and myze make executive additions
Check out the latest leadership news from the eyecare space, including a new CEO at ViaLase and a leading optometrist joining myze.Business
Alcon to purchase LumiThera
Targeting a Q3 sale, acquisition includes Valeda Light Delivery System, the first and only PBM treatment for early-to-intermediate dry AMD.
Events
Alcon offers first look at TRYPTYR, debuts new innovations for contact lens ordering app
Company announces partnership with Revolution EHR to advance its MARLO platform; highlights new dry eye and contact lens offerings.Products
FDA approves Alcon's TRYPTYR (acoltremon ophthalmic solution) 0.003% for DED
The prescription-based eye drop is the first that stimulates corneal nerves to directly address tear deficiency; company plans for a Q3 2025 U.S. launch.
Products